British drugmaker Shire (SHP.L) hopes to generate "multiple billions of dollars" of extra sales from expanded use of the hyperactivity drug Vyvanse into new indications, such as schizophrenia and depression, the company's CEO said on Wednesday.
Since Vyvanse is a stimulant, some analysts have questioned how willing regulators will be to see its use extended into wider population groups.
However, Shire Chief Executive Angus Russell told the Reuters Health Summit that the U.S. Food and Drug Administration was backing the company's moves to test the medicine among patients who had failed on standard therapy. Early tests have shown promise, he said.
